1
|
Batchi-Bouyou AL, Djontu JC, Ingoba LL, Mougany JS, Mouzinga FH, Dollon Mbama Ntabi J, Kouikani FY, Christ Massamba Ndala A, Diafouka-Kietela S, Ampa R, Ntoumi F. Neutralizing antibody responses assessment after vaccination in people living with HIV using a surrogate neutralization assay. BMC Immunol 2024; 25:43. [PMID: 38987686 PMCID: PMC11234560 DOI: 10.1186/s12865-024-00625-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 06/01/2024] [Indexed: 07/12/2024] Open
Abstract
OBJECTIVE HIV has been reported to interfere with protective vaccination against multiple pathogens, usually through the decreased effectiveness of the antibody responses. We aimed to assess neutralizing antibody responses induced by COVID-19 vaccination in PLWH in Brazzaville, Republique of the Congo. METHOD The study was conducted at the Ambulatory Treatment Center of the National HIV Program, in charge of over 6000 PLWH, and the health center of FCRM in Brazzaville, Republic of the Congo. Participants were divided into two groups: PLWH with well-controlled HIV infection (CD4 counts no older than one week ≥ 800 / mm3, undetectable viral load of a period no older than one week and regularly taking Highly Active Antiretroviral Therapy for at least 6 months) and PLWOH. These groups were subdivided by vaccination status: fully vaccinated with adenovirus-based vaccines (Janssen/Ad26.COV2.S and Sputnik/Gam-COVID-Vac) or inactivated virus vaccine (Sinopharm/BBIP-CorV) and a control group of unvaccinated healthy individuals. All participants were RT-PCR negative at inclusion and/or with no documented history of SARS-CoV-2 infection. ELISA method was used for detecting IgG and neutralizing Antibodies against SARS-CoV-2 antigens using a commercial neutralizing assay. RESULTS We collected oropharyngeal and blood samples from 1016 participants including 684 PLWH and 332 PLWOH. Both PLWH and PLWOH elicited high levels of antibody responses after complete vaccination with inactivated virus vaccine (Sinopharm/BBIP-CorV) and adenovirus-based vaccines (Janssen/Ad26.COV2.S and Sputnik/Gam-COVID-Vac). Overall, no difference was observed in neutralization capacity between PLWOH and PLWH with well-controlled HIV infection. CONCLUSION The results from this study underline the importance of implementing integrated health systems that provide PLWH the opportunity to benefit HIV prevention and care, at the same time while monitoring their vaccine-induced antibody kinetics for appropriate booster schedules.
Collapse
Affiliation(s)
- Armel Landry Batchi-Bouyou
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo.
- Global Clinical Scholars Research Training Program, Harvard Medical School, Boston, MA, USA.
- Department of Medicine, School of Medicine, Washington University in St Louis, St Louis, MO, 63130, USA.
| | - Jean Claude Djontu
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo
| | - Line Lobaloba Ingoba
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo
| | - Jiré Séphora Mougany
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo
| | - Freisnel Hermeland Mouzinga
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo
| | - Jacques Dollon Mbama Ntabi
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo
| | - Franck Yannis Kouikani
- Department of Health and Social Care, Ministry of Higher Education, Scientific Research and Technological Innovation, Brazzaville, Republic of the Congo
| | - Arcel Christ Massamba Ndala
- Ambulatory Treatment Center, National HIV Program, Ministry of Health and Population, Brazzaville, Republic of the Congo
| | - Steve Diafouka-Kietela
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo
| | - Raoul Ampa
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of the Congo
| | - Francine Ntoumi
- Fondation Congolaise pour la Recherche Médicale (FCRM), Villa D6, Campus OMS, Djoué, Brazzaville, Republic of the Congo.
- Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
| |
Collapse
|
2
|
Ferrari L, Ruggiero A, Stefani C, Benedetti L, Piermatteo L, Andreassi E, Caldara F, Zace D, Pagliari M, Ceccherini-Silberstein F, Jones C, Iannetta M, Geretti AM. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection. Sci Rep 2024; 14:8337. [PMID: 38594459 PMCID: PMC11003986 DOI: 10.1038/s41598-024-58597-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 04/01/2024] [Indexed: 04/11/2024] Open
Abstract
Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population.
Collapse
Affiliation(s)
- Ludovica Ferrari
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy
| | - Alessandra Ruggiero
- Department of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Verona, Italy
| | - Chiara Stefani
- Department of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Verona, Italy
| | - Livia Benedetti
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | | | - Eleonora Andreassi
- Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Federica Caldara
- Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy
| | - Drieda Zace
- Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy
| | - Matteo Pagliari
- Laboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale Delle Venezie, Legnaro, Italy
| | | | - Christopher Jones
- Department of Primary Care and Public Health, Brighton and Sussex Medical School, Falmer, UK
| | - Marco Iannetta
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy
| | - Anna Maria Geretti
- Department of Infectious Diseases, Fondazione PTV, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
- Department of Infection, North Middlesex University Hospital, London, UK.
- School of Immunity & Microbial Sciences, King's College London, London, UK.
| |
Collapse
|
3
|
Bertoletti A. SARS-CoV-2 immunity. Cell Mol Immunol 2024; 21:101-102. [PMID: 38238439 PMCID: PMC10805843 DOI: 10.1038/s41423-024-01128-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Accepted: 01/03/2024] [Indexed: 01/25/2024] Open
Affiliation(s)
- Antonio Bertoletti
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
| |
Collapse
|
4
|
Müller SA, Isaaka L, Mumm R, Scheidt-Nave C, Heldt K, Schuster A, Abdulaziz M, El-Bcheraoui C, Hanefeld J, Agweyu A. Latent viral infections as neglected risk factors for long COVID - Authors' reply. Lancet Glob Health 2024; 12:e198. [PMID: 38245110 DOI: 10.1016/s2214-109x(23)00595-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Accepted: 12/11/2023] [Indexed: 01/22/2024]
Affiliation(s)
- Sophie Alice Müller
- Centre for International Health Protection, Robert Koch Institute, Berlin 13353, Germany.
| | - Lynda Isaaka
- KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Rebekka Mumm
- Epidemiology and Health Monitoring, Robert Koch Institute, Berlin 13353, Germany
| | - Christa Scheidt-Nave
- Epidemiology and Health Monitoring, Robert Koch Institute, Berlin 13353, Germany
| | - Katharina Heldt
- Methods Development, Research Infrastructure and Information Technology, Robert Koch Institute, Berlin 13353, Germany
| | - Angela Schuster
- Centre for International Health Protection, Robert Koch Institute, Berlin 13353, Germany; Institute of General Practice and Family Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Mohammed Abdulaziz
- Division of Disease Control and Prevention, Africa CDC, Addis Ababa, Ethiopia
| | - Charbel El-Bcheraoui
- Evidence-based Public Health, Centre for International Health Protection, Robert Koch Institute, Berlin, Germany
| | - Johanna Hanefeld
- Centre for International Health Protection, Robert Koch Institute, Berlin 13353, Germany
| | - Ambrose Agweyu
- KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya; London School of Hygiene and Tropical Medicine, London, UK
| |
Collapse
|
5
|
Holdenrieder S, Dos Santos Ferreira CE, Izopet J, Theel ES, Wieser A. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19. Front Public Health 2023; 11:1290402. [PMID: 38222091 PMCID: PMC10788057 DOI: 10.3389/fpubh.2023.1290402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 11/30/2023] [Indexed: 01/16/2024] Open
Abstract
Much of the global population now has some level of adaptive immunity to SARS-CoV-2 induced by exposure to the virus (natural infection), vaccination, or a combination of both (hybrid immunity). Key questions that subsequently arise relate to the duration and the level of protection an individual might expect based on their infection and vaccination history. A multi-component composite correlate of risk (CoR) could inform individuals and stakeholders about protection and aid decision making. This perspective evaluates the various elements that need to be accommodated in the development of an antibody-based composite CoR for reinfection with SARS-CoV-2 or development of severe COVID-19, including variation in exposure dose, transmission route, viral genetic variation, patient factors, and vaccination status. We provide an overview of antibody dynamics to aid exploration of the specifics of SARS-CoV-2 antibody testing. We further discuss anti-SARS-CoV-2 immunoassays, sample matrices, testing formats, frequency of sampling and the optimal time point for such sampling. While the development of a composite CoR is challenging, we provide our recommendations for each of these key areas and highlight areas that require further work to be undertaken.
Collapse
Affiliation(s)
- Stefan Holdenrieder
- Institute of Laboratory Medicine, German Heart Centre Munich, Technical University Munich, Munich, Germany
| | | | - Jacques Izopet
- Laboratory of Virology, Toulouse University Hospital and INFINITY Toulouse Institute for Infections and Inflammatory Diseases, INSERM UMR 1291 CNRS UMR 5051, University Toulouse III, Toulouse, France
| | - Elitza S. Theel
- Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- German Centre for Infection Research (DZIF), Munich, Germany
- Faculty of Medicine, Max Von Pettenkofer Institute, LMU Munich, Munich, Germany
- Immunology, Infection and Pandemic Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Munich, Germany
| |
Collapse
|